Madrigal Pharmaceuticals(MDGL) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Madrigal Pharmaceuticals Reports Second-Quarter 2024 Financial Results and Provides Corporate Updates • Second-quarter 2024 net sales of $14.6 million • Rezdif ra™ (resmetirom) coverage in place for more than 50 percent of commercial lives; less than 5 percent of Rezdif ra-covered lives require biopsy • Expert guidelines recommend Rezdif ra as first-line therapy for patients with F2/F3 NASH/MASH • Plans to directly commercialize resmetirom in Europe following EMA decision expected mid-year 2025 ...